Study offers a differentiated patient-specific solution in minimal residual disease testing
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
Analysis of DNA shed into a patient s blood stream can provide a noninvasive means of detecting the presence of a tumor. Patients who have undergone initial treatment may only have small amounts of tumor DNA in their blood, which can be difficult to detect with conventional technology. TARDIS was developed to be highly sensitive and customizable for each patient, including those with only a trace amount of tumor remaining following surgery or other localized treat
Radiological imaging of melanoma: a review to guide clinical practice in New Zealand
Open Access
PDF Download
The aim of this review is to propose guidelines for initial radiological staging and the follow-up imaging regime for melanoma. This will provide consistency in the access and delivery of quality melanoma care. Radiological imaging plays an important role in assessing the extent of disease, guiding individual treatment and evaluating treatment response. However, there exists limited literature addressing the optimal radiological staging and surveillance imaging regimes for melanoma. The lack of consensus on imaging for melanoma can generate inconsistency in the standard of skin cancer care provided. This review considers the appropriate imaging techniques for both initial melanoma staging and follow-up specifically in the New Zealand clinical environment. The recommendations in this article are based on evaluation of the currently available literature and consensus of fee
Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer Network
PLYMOUTH MEETING, Pa., Jan. 14, 2021 /PRNewswire/ The National Comprehensive Cancer Network (NCCN
)-an alliance of leading cancer centers-today announced the appointment of
Crystal S. Denlinger, MD, FACP, to the newly-created role of Senior Vice President, Chief Scientific Officer. In this position, Dr. Denlinger will help to steer strategic direction for the nonprofit as well as oversee the NCCN Oncology Research Program (ORP). Her duties will also involve providing input into NCCN s clinical information program, including the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
), as well as various continuing education activities.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.